NEWSEEN COAST

Newseen Coast is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on high-prevalence metabolic diseases, oncology, and autoimmune disorders, leveraging a robust internal research and development platform. Its lead program, NC001, is a highly selective thyroid hormone receptor beta (THR-beta) agonist designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and hyperlipidemia. Beyond metabolic health, Newseen Coast is advancing a pipeline of candidates targeting various oncological pathways and inflammatory mechanisms. The company has successfully secured significant venture capital funding from prominent investors to support its clinical trials and expansion. Newseen Coast aims to provide effective and accessible treatment options for patients with chronic and life-threatening conditions worldwide.